05/23/2002 By David Loshak
Anti-E-selectin is ineffective in the treatment of chronic plaque psoriasis even though it is a well-tolerated, logical and safe therapy.
This finding of a randomised trial is reported by dermatologists and other specialists based at the University of Manchester, Salford, England.
The doctors noted that skin-homing, memory T lymphocytes play an important part in the pathogenesis of psoriasis by interacting with the vascular addressin, E-selectin and trafficking into lesional skin. This suggested blockade of skin-homing T cells with an antibody directed at E-selectin as an attractive option for targeted therapy of the disease.
A multicentre, randomised, placebo-controlled trial to investigated the clinical efficacy and side-effects of a humanised monoclonal antibody to E-selectin, CDP850, for moderate to severe chronic plaque psoriasis. Nine men aged 25-47 years received 20 mg/Kg-1 CDP850 intravenously as a single dose and three men and one woman aged 25-50 years received placebo infusions.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!